% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kiss:140404,
author = {Kiss, Róbert and Csizmadia, Georgina and Solti, Katalin
and Keresztes, Attila and Zhu, Max and Pickhardt, Marcus and
Mandelkow, Eckhard and Tóth, Gergely},
title = {{S}tructural {B}asis of {S}mall {M}olecule {T}argetability
of {M}onomeric {T}au {P}rotein.},
journal = {ACS chemical neuroscience},
volume = {9},
number = {12},
issn = {1948-7193},
address = {Washington, DC},
publisher = {ACS Publ.},
reportid = {DZNE-2020-06726},
pages = {2997 - 3006},
year = {2018},
abstract = {The therapeutic targeting of intrinsically disordered
proteins (IDPs) by small molecules has been a challenge due
to their heterogeneous conformational ensembles. A potential
therapeutic strategy to alleviate the aggregation of IDPs is
to maintain them in their native monomeric state by small
molecule binding. This study investigates the structural
basis of small molecule druggability of native monomeric Tau
whose aggregation is linked to the onset of Tauopathies such
as Alzheimer's disease. Initially, two available monomeric
conformational ensembles of a shorter Tau construct K18
(also termed Tau4RD) were analyzed which revealed striking
structural differences between the two ensembles, while
similar number of hot spots and small molecule binding sites
were identified on monomeric Tau ensembles as on tertiary
folded proteins of similar size. Remarkably, some critical
fibril forming sequence regions of Tau (V306-K311,
V275-K280) participated in hot spot formation with higher
frequency compared to other regions. As an example of small
molecule binding to monomeric Tau, it was shown that
methylene blue (MB) bound to monomeric K18 and full-length
Tau selectively with high affinity (Kd = 125.8 nM and 86.6
nM, respectively) with binding modes involving Cys291 and
Cys322, previously reported to be oxidized in the presence
of MB. Overall, our results provide structure-based evidence
that Tau can be a viable drug target for small molecules and
indicate that specific small molecules may be able to bind
to monomeric Tau and influence the way in which the protein
interacts among itself and with other proteins.},
keywords = {Humans / Intrinsically Disordered Proteins: metabolism /
Methylene Blue: metabolism / Molecular Docking Simulation /
Molecular Targeted Therapy / Neurofibrillary Tangles:
metabolism / Protein Structure, Tertiary / Tauopathies:
metabolism / tau Proteins: chemistry / tau Proteins:
metabolism / tau Proteins: ultrastructure / Intrinsically
Disordered Proteins (NLM Chemicals) / MAPT protein, human
(NLM Chemicals) / tau Proteins (NLM Chemicals) / Methylene
Blue (NLM Chemicals)},
cin = {AG (Eckhard) Mandelkow},
ddc = {540},
cid = {I:(DE-2719)1013014},
pnm = {342 - Disease Mechanisms and Model Systems (POF3-342)},
pid = {G:(DE-HGF)POF3-342},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29944336},
doi = {10.1021/acschemneuro.8b00182},
url = {https://pub.dzne.de/record/140404},
}